c Mother-to-child transmission (MTCT) of HIV-1 remains a global health problem. The World Health Organization (WHO) recommendations advise the administration of a once-daily, oral, prophylactic regimen of the nonnucleoside reverse transcriptase inhibitor nevirapine (NVP) from birth until 4 to 6 weeks of age for infants born to HIV-infected mothers in regions without access to safe and nutritionally adequate alternatives to breast milk. A critical factor driving the successful implementation of the WHO guidelines involves sustaining high adherence to the frequent dosing. With these challenges in mind, we have developed the first injectable, sustained-release NVP formulations with the goal of providing, for 6 weeks or longer, preventative plasma drug levels from a single subcutaneous administration at birth. The long-acting NVP consists of large (>50 m), monodisperse NVP particles coated with biocompatible polymers that control the drug release kinetics. Two lead formulations exhibiting burst-free, sustained-release kinetics for up to 75 days in vitro were developed. Subsequent in vivo studies in rats demonstrated no toxicity related to the formulations. Rat plasma NVP concentrations were above the analytical assay's limit of quantification for up to 28 days. Pharmacokinetic analysis of the rat plasma NVP concentration-time data allowed absorption rate constants to be calculated. These data then were used to simulate infant NVP exposure from a single injected dose (<200 mg) of our longacting formulations, demonstrating preliminary feasibility of the technology to maintain safe, preventative NVP plasma levels (0.2 to 3.0 g ml ؊1 ) for 6 weeks or longer.
M other-to-child transmission (MTCT) of HIV-1 remains a global health problem (1) . In 2008, an estimated 1.4 million HIV-infected women gave birth in low-and middle-income countries, resulting in 430,000 new pediatric infections (2) . In breastfeeding populations and in the absence of a prevention strategy, the MTCT rate has been estimated to be 25 to 45% (3) . Administration of highly active antiretroviral therapy (HAART) to pregnant HIV-infected women is effective for preventing MTCT (2) , but access to HAART is limited in resource-constrained regions, where Ͼ90% of HIV-1-infected pregnant women reside (2) .
HIV prevention programs aim to reduce MTCT to Ͻ5% using antiretroviral prophylaxis (2) . Interventions currently target the peripartum/neonatal period (3) . The most widely used regimen is derived from the HIVNET 012 study, which demonstrated that oral administration of the nonnucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (NVP) to the mother at labor onset (a single 200-mg dose) and a 2 mg kg of body weight Ϫ1 dose administered to the infant within 72 h of birth reduced transmission by half (4, 5) .
A significant risk of vertical transmission of HIV in breastfed infants occurs within the first 6 weeks postpartum (6, 7) . As a result, the World Health Organization (WHO) recommendations advise the administration of an antiretroviral prophylactic regimen consisting of once-daily oral NVP (10-to 15-mg dose, depending on birth weight) from birth until 4 to 6 weeks of age for infants born to HIV-infected mothers in regions without access to safe and nutritionally adequate alternatives to breast milk (2) .
A critical factor determining the successful implementation of the WHO guidelines of daily NVP administration to breastfeeding infants for 4 to 6 weeks is sustaining high adherence to the frequent dosing. It has been well established across different delivery methods that adherence to therapy is inversely related to the dosing period (8) (9) (10) (11) . In addition, the amount of health care resources required for a treatment or prevention strategy in the developing world is directly proportional to the required dosing frequency (12, 13) . For this reason, much effort has been expended to reduce the dosing frequency in tuberculosis eradication campaigns, where a twice-a-week regimen is considered a significant advance over daily dosing (14) . Sustained-release drug delivery holds significant promise as a means of reducing the dosing frequency and thus increasing the effectiveness of HIV prophylaxis with NVP.
There have been a few reports on sustained-release NVP. Chen and colleagues described a subcutaneous NVP implant that exhibited excellent in vitro-in vivo correlation in rats and demonstrated the long-term safety and feasibility of the concept of sustainedrelease NVP (15) . However, surgical implantation is a major drawback, especially in resource-limited settings. Additionally, because the implant is visible under the skin, the possibility of stigmatization makes this approach potentially dangerous for the mother and child (16) .
Here, the first report on injectable sustained-release NVP formulations is presented. The goals of the research were to measure the in vitro release profiles of polymer-coated NVP microparticles, to evaluate the pharmacokinetics (PK) of the formulations in vivo using a rat model, and to simulate the PK in human neonates. The results demonstrate the preliminary feasibility of the technology for maintaining safe and preventative NVP plasma levels for 6 weeks or longer with a single injectable dose.
MATERIALS AND METHODS
Materials. Nevirapine (NVP) was obtained from Sinobright Import Export Co., Ltd. (China) and was used as received. The identity and purity of the drug substance were confirmed by 1 H nuclear magnetic resonance (NMR) spectroscopy and melting point measurement. Poly(vinyl alcohol) (PVA) with a mean molecular weight (M w ) of 145,000 was obtained from Sigma-Aldrich (St. Louis, MO). Two poly(D,L-lactide) (PLA) polymers were used: M w of 250,000 (Fluka Chemical Corp., St. Louis, MO) and M w of 10,000 (Resomer R 202 S; Boehringer-Ingelheim, Petersburg, VA).
Formulation of the NVP long-acting 1 (LA-1) microparticle suspension. Nevirapine powder (90% of particles of Ͻ5 m) was compacted at 0.62 GPa, resulting in the formation of "hyalinized" wafers that were glassy, translucent, and friable and approximately 150 m thick. The wafers were gently pressed through a standard (U.S. standard ASTM E 11-61 specification) number 45 sieve (355-m mesh opening) with a glass rod and collected on a number 50 sieve (300-m mesh opening) as rough cubes. The particles were dip coated with a 1% (wt/vol) PVA solution in deionized water five successive times, heat treated at 150°C for 1 h, spray coated with a 5% (wt/vol) PLA (M w of 250,000) solution in dichloromethane-ethyl acetate (1:1, vol/vol) five successive times and dip coated in a 1% (wt/vol) PLA and PVA solution five times, followed by another five coats of PLA. The polymer content of the formulation was measured by quantitative 1 H NMR (qNMR) spectroscopy using the following peaks: ␦ H , 7.0 to 7.3 ppm (NVP), 5.0 to 5.3 ppm (PLA), and 4.4 to 4.7 ppm (PVA). The particle size distribution was measured by laser diffraction with a model LS100Q (Beckman-Coulter, Brea, CA) dynamic light-scattering analyzer and use of a Fraunhofer optical model. The thickness of the polymer membrane was calculated based on these measurements, assuming that the shape is an idealized cuboidal, the diameter measured by laser diffraction equals the space diagonal of the cube, and the densities of the drug and polymers are equal.
Formulation of the NVP long-acting 2 (LA-2) microparticle suspension. Nevirapine powder was recrystallized from reagent alcohol to afford cuboidal crystals that were filtered in vacuo and collected on a sieve stack between a number 60 sieve (250-m mesh opening) and a number 80 sieve (180-m mesh opening). The particles were coated using a model MFL.01 Micro Flo-Coater (Vector Corporation, Marion, IA) fluidized bed system and a 5% (wt/vol) PLA (M w of 10,000) solution in dichloromethane-ethyl acetate (1:1, vol/vol). The PLA content of the formulation was determined by qNMR spectroscopy as described above. The particle size distribution and polymer membrane thickness were determined as above.
In vitro release kinetics measurements. To each of six vessels (1 liter) in a USP type II dissolution system, deionized water (500 ml) and the NVP test formulation (ca. 2 mg) were added, and the suspension was stirred at 30 rpm and ambient temperature (26 to 30°C). Aliquots (3 ml) were removed from the vessels at predetermined time points and replaced with deionized water. The samples were analyzed by UV spectroscopy to determine the NVP concentration ( max ϭ 215 nm). The NVP release halflife (t 1/2 ) was calculated by fitting the kinetics data to a single exponential decay equation model, and the absorption rate constant (K) was calculated as ln 2/t 1/2 .
Animals. Two animal studies were carried out at Charles River Laboratories (Shrewsbury, MA) under approved internal institutional animal care and use committee protocols and standard guidelines according to the Guide for the Care and Use of Laboratory Animals (DHEW no. NIH 86-23). Study 1 (JNN00006, March 2006) evaluated the PK and toxicity of subcutaneous NVP long-acting 1 (NVP LA-1) in Sprague-Dawley rats (n ϭ 4, mean weight of 0.33 kg). Study 2 (JNN00030, May 2009) evaluated the PK and toxicity of subcutaneous NVP LA-2 in Sprague-Dawley rats (n ϭ 10, mean weight of 0.21 kg). All animals were housed under standard conditions and had ad libitum access to water and a standard laboratory diet. Euthanasia (carbon dioxide asphyxiation followed by thoracotomy) was performed in accordance with accepted American Veterinary Medical Association (AVMA) guidelines.
NVP LA administration and sampling. Doses were administered once via subcutaneous injection: study 1, 60 mg NVP LA-1 suspension in 1 ml saline injected via a 14-G needle; study 2, NVP LA-2 suspension, weight-adjusted dose of 36 mg kg Ϫ1 (dose concentration, 12 mg ml Ϫ1 in 1% [wt/wt] carboxymethylcellulose) injected via an 18-G needle. Blood samples were collected at predetermined time points: for study 1 on days 1 (1 and 6 h postdose), 2, 3, 4, 6, 10, 14, and 28; for study 2 on days Ϫ7, 1 (1, 3, 7, and 12 h postdose), 2, 3, 7, 14, 21, and 28. Blood samples (0.5 ml) were collected from the jugular vein into tubes containing K 2 EDTA and stored on wet ice before being processed for plasma. Plasma samples were stored and transported at Ϫ70°C.
Assessment of toxicity. The toxicity was evaluated by monitoring clinical observations, cageside observations, and body weight. A complete gross necropsy was conducted on all animals. The necropsy included examination of the carcass and musculoskeletal system, all external surfaces and orifices, the cranial cavity and external surface of the brain, and all thoracic, abdominal, and pelvic cavities with their associated organs and tissues. All abnormalities were described and recorded. The tissues from the administration site were examined in situ, dissected free, and fixed in 10% neutral buffered formalin or other suitable fixative. The tissue specimens were embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The tissue specimens were read and interpreted by a veterinary pathologist with training and experience in laboratory animal pathology.
Analysis of NVP in rat plasma. Plasma samples from both studies were analyzed at the Charles River Laboratories using the bioanalytical methods described below. Both had a lower limit of quantitation (LLOQ) of 1 ng ml Ϫ1 NVP. In study 1, thawed plasma sample aliquots (25 l) were transferred to 96-well plates followed by the addition of internal standard (IS) solution (0.25 g ml Ϫ1 glyburide in acetonitrile, 100 l). The samples were mixed by vortex agitation, followed by centrifugation (5 min), and transferred to a new plate where they were dried under a nitrogen stream. The samples were reconstituted in 100 l 10% (vol/vol) acetonitrile in water prior to analysis. The concentration of NVP was determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a high-performance liquid chromatography (HPLC) system consisting of series 200 micropumps (PerkinElmer, Shelton, CT) interfaced to an API 5000 mass spectrometer (Applied Biosystems, Concord, ON, Canada) using a Thermo Scientific (Waltham, MA) Hypersil Gold column In study 2, thawed plasma sample aliquots (25 l) were transferred to 96-well plates followed by the addition of internal standard solution (0.10 g ml Ϫ1 reserpine in acetonitrile, 100 l). The samples were mixed by vortex agitation, followed by centrifugation (5 min), and transferred to a new plate, and Milli-Q water (50 l) was added to all samples. The concentration of NVP was determined by LC-MS/MS using an HPLC system consisting of series 200 micropumps (PerkinElmer) interfaced to an API 4000 mass spectrometer (Applied Biosystems) using a Waters (Waltham, MA) X-Terra C 18 column (2.1 by 30 mm; 3.5 m) at ambient temperature as the stationary phase. The following gradient program was used: 0. Pharmacokinetic analysis software. The population PK modeling and simulations were performed using Phoenix NLME software (version 6.3.0.395; Pharsight Corporation, Sunnyvale, CA). Data set preparation, exploration, and visualization of the data were performed using Microsoft Excel, Phoenix, or GraphPad Prism (version 6.02; GraphPad Software, Inc.).
Population PK data set construction. A population PK data set was constructed based on data collected in rats. The data set included the nominal times of NVP dose administration and of blood sampling collection. For study 1, it was assumed that 75% of the dose was received by the animal, i.e., 45 mg (135 mg kg Ϫ1 ), due to injection inefficiencies. For study 2, it was assumed that 80% of the intended dose was received, i.e., 6.7 mg (29 mg kg Ϫ1 ). Concentrations below the lower limit of quantification (BLLOQ) of the assay were set as missing.
Population PK model development. The population PK analysis was performed in a stepwise manner by modeling plasma drug concentration data following subcutaneous administration in rats of the long-acting NVP. Prior to performance of modeling and simulations, a visual inspection of the mean and individual concentration-time profiles was performed to identify possible outliers (subjects and concentrations) and candidate structural PK models. A basic structural PK model was used for fitting the plasma drug concentration versus time data obtained from preclinical studies. The goodness of fit (GOF) was evaluated using diagnostic plots and related statistical estimators.
Structural PK model buildup. Various compartmental PK models were constructed to assess the PK. For example, 1-and 2-compartment models with linear disposition were compared. In general, the models consisted of the following: description of the relationships between plasma NVP concentrations and time and the residual component describing uncertainty in the state of knowledge about the critical model components. The population PK model had the following form:
where C pij is the concentration at the jth time (t j ) for animal i, D i represents the dosing history for animal i, i is the vector of m model parameters for animal i, and ε ij is the random error associated with the jth concentration for animal i.
Due to the low number of rats (n ϭ 4 or n ϭ 10) available for each formulation, no between-subject variability (BSV) was added in the PK model although various residual error models were evaluated. Residual variability was nominally assumed to have an additive component and a component proportional to the prediction:
where y ij and ŷ ij represent the jth observed and predicted plasma drug concentrations for the ith participant, and is the random residual variability. Each ( 1 and 2 ) is normally distributed with mean 0 and variance 2 . This model can be simplified to an additive only model ( 1 ϭ 0) or proportional only model ( 2 ϭ 0).
The robustness of the NVP PK parameters was evaluated using graphical tools and statistical estimators (see Fig. S1 and S2 in the supplemental material). Model evaluation and selection of the structural model were based on (i) the model acceptability according to the pharmacology and physiology of the drug; (ii) the statistical standard criteria of GOF, such as the log-likelihood difference between rival models (e.g., a decrease in the minimum objective function value, Ϫ2LL); and (iii) the pertinent graphical representations of GOF (e.g., fitted and observed concentrations versus time and residuals versus time) and precision of the parameter estimates. The naive pooled approach was used.
Equations describing the allometric scaling of interspecies PK parameters are based on the premise that physical or physiological parameters in species vary as a function of body weight (17, 18 (3) where i is the value of the parameter for the ith individual, Typical is the typical value of the PK parameter for an individual having the covariate equal to the covariate reference value, Cov i is the value of the covariate for the individual, Cov reference value is the median of the covariate in the animals, and eff is the value of the effect of the covariate on the parameter. The nominal covariate effect was Ϫ0.25 on absorption rate, 1 on volumes, and 0.75 on clearance (19) .
Human simulations. Infant parameters for the human simulations were compiled from recent clinical studies in Uganda examining the population PK of single-dose NVP in breastfeeding infants of HIV-positive mothers (20, 21) . The newborns' weights ranged from 2.0 to 3.9 kg, and the following systemic parameters were determined from population PK estimates: V/bioavailability (F), 20.0 liters; CL/F, 0.21 liters h Ϫ1 ; and t 1/2 , 66 h. These systemic parameters were combined with presystemic rat parameters, essentially the absorption rate constant, k a , in order to simulate human exposure. Simulations were performed using a naive-pooled approach to estimate the mean plasma drug concentrations in humans.
Statistical analysis. Data set group statistics (medians and standard deviations [SD] ) and plots were carried out using GraphPad Prism.
RESULTS

Physical characteristics of the long-acting NVP formulations.
The physical characteristics of the sustained-release microparticle NVP formulations are presented in Table 1 and Fig. 1 . The orangebrown color of NVP LA-1 (Table 1) is the result of dehydration of the PVA backbone during thermal processing, leading to conjugated double bonds (22, 23) . In vitro cumulative release profiles ( Fig. 2; Table 1 ) from both formulations exhibited burst-free, sustained release for up to 75 days and could be fit to a simple exponential decay model. Toxicity. No adverse events related to the test material were noted during the course of the studies. Overall, no significant ab- normalities were observed. The animals showed no failure to eat or drink, no failure to groom, and no weight loss. There was no clinical evidence of inflammation at the injection sites. In general, inflammation within the skin sections examined was uncommon and confined to the subpannicular fascia.
Of the nine skin sections examined in study 1, only four sections (i.e., both middle and caudal injection sites of two animals [ID 02 and 03] contained evidence of cellular infiltrate/inflammation. Within primarily the subpannicular fascia, there were scattered to regional, and sometimes perivascular, minimal mild chronic inflammation (i.e., admixture of histiocytes/macrophages, lymphocytes, and/or plasma cells) that was typically admixed with widespread variable numbers of foamy macrophages with a granular to fibrillar cytoplasmic content. Also noted in the subpannicular fascia of two animals (ID 02 and 03) was a foreign body reaction characterized by aggregates of multinucleated giant cells and macrophages, associated with fragments of a basophilic polymorphic granular to smooth material interpreted as residual capsular material from the test article. This mild chronic inflammatory reaction is consistent with other reports in the literature of responses to the injection of other approved drug delivery systems based on polylactic acid polymers (24) .
In study 2, one animal (ID 03) had abrasions on both shoulders and scabs on the right shoulder and abdomen. No visible lesions were observed on tissues and organs collected after necropsy, including the administration site.
Pharmacokinetics of sustained-release NVP in rats. Rat plasma NVP concentration versus time plots following a single subcutaneous dose are shown in Fig. 3 . These data were fit to compartmental PK models in order to assess the absorption rate of each formulation. Pharmacokinetic parameters are presented in Table 2 .
Human simulation. Human (2.0 and 3.9 kg body weight) simulations of plasma NVP concentration versus time plots following a single subcutaneous dose are shown in Fig. 4 . The bioavailable fraction was assumed to be 100% in these simulations.
DISCUSSION
The primary objectives of the current study were to develop sustained-release injectable formulations of NVP, measure the PK of the formulations in rats, and use the PK data to simulate the PK of the formulations in human infants. The results are discussed below with an emphasis on HIV prophylaxis in breastfeeding infants.
Long-acting parenteral antiretroviral therapy and HIV prophylaxis. Daily dosing is burdensome to the user, leading to concomitant adherence-related issues in HIV prevention and the treatment of HIV/AIDS. As a result, long-acting antiretroviral therapy (LA-ART) and long-acting preexposure prophylaxis (LAPrEP) have emerged recently as alternative regimens (25) (26) (27) . These efforts primarily have focused on nanomilled formulations of the antiretroviral (ARV) drugs, allowing them to be administered parenterally as injections (25, 26) . The ARV drugs atazanavir and ritonavir, nanoformulated in poloxamer 188 excipient by high-pressure homogenization, were evaluated preclinically as LA-ART candidates in humanized mouse (28) and nonhuman primate models (29) . Parenteral administration of the integrase strand-transfer inhibitor GSK1265744 (GSK744) fully protected rhesus macaques against repeated low-dose intrarectal challenges of SHIV162P3 (30) . Monthly or bimonthly injections of longacting nanoparticulate formulations of GSK744 and the non- nucleoside reverse transcriptase inhibitor rilpivirine (RPV) are being investigated clinically as possible regimens for HIV therapy (25, 27, 31) . HIV prophylaxis using long-acting NVP formulations. Parenteral long-acting ARV regimens require infrequent dosing (e.g., monthly) to be suitable for HIV PrEP (25) . In the case of NVP for prevention of HIV infection in breastfeeding infants, a single dose should provide prophylactic systemic drug exposure for 6 weeks, in accordance with the WHO guidelines (2). The dosing frequency of ARV nanoformulations is determined by the aqueous solubility of the drug, the antiviral potency, and the systemic clearance kinetics. These criteria severely limit the number of FDA-approved ARV agents suitable for reformulation as nanoparticles (25) . Surface-modified NVP nanosuspensions were developed for organtargeted delivery and evaluated in the rat model (32) . Bare and surface-modified NVP nanoparticles did not maintain detectable plasma levels beyond 24 h, suggesting that an alternative drug delivery approach is required.
A novel approach to sustained delivery of ARV agents. The long-acting parenteral depot drug delivery system described here differs significantly from the more widely used nanoparticle formulations and microspheres produced by emulsion-solvent evaporation, consisting of a drug encapsulated within a biodegradable polymer matrix. Our approach involves large (Ͼ50-m) particles consisting of solid drug cores coated with thin, biocompatible polymer membranes ( Table 1) . The dissolution by surface action of a solid particle suspended in liquid medium can be described in terms of the Noyes-Whitney equation (33) , where the rate of dissolution is directly proportional to the particle surface area. Largeparticle depots also greatly increase the drug payload compared to that for the more common small-particle (Ͻ10 m) formulations. For example, a micronized drug particle of 7 m in diameter with a 5-m coating has a drug loading of only 10% (34), whereas our NVP LA-1 is made up of 411-m particles with a 13-m-thick coating, affording a drug loading of 71% (Table 1) .
Both NVP LA formulations consist predominantly of large particles (median d p , Ͼ200 m for both formulations) ( Table 1) with high monodispersity (Fig. 1) . This observation is supported by the degree of observed kurtosis (Table 1) , suggesting a leptokurtic distribution where the size of the majority of particles is close to the mean size. The negative skewness values (Table 1) suggest a deviation from idealized symmetry, with tailing at the fine particle sizes.
The relatively small membrane thickness in both candidates ensures that transmembrane flux determines the kinetics of dissolution. While both formulations displayed first-order dissolution kinetics in vitro, NVP LA-1 released its drug payload considerably faster than NVP LA-2. The half-life of release, t 1/2 , of NVP LA-2 was 5.7 times higher than that for NVP LA-1 (Table 1) . This is likely due to a more even coating of the blocking polymer (PLA) in NVP LA-2 obtained by the fluidized bed coating, rather than the manual spray coating used for NVP LA-1.
Our formulation strategy results in the absence of a burst in initial release (Fig. 2) , a nontrivial finding, as all sustained-release parenteral suspensions currently marketed have significant burst effects (35, 36) . The absence of a concentration burst makes the novel drug delivery strategy described here translational to other therapeutic arenas where controlled drug release within a target concentration window is important for favorable pharmacodynamic outcomes.
Pharmacokinetics of sustained-release NVP in rats. PK parameters from both studies are summarized in Table 2 . It should be noted that the values of V and CL derived from the models (Table 2) do not correspond to "true" systemic and peripheral parameters as would be obtained following intravenous (i.v.) dosing. Rather, these values represent formulation-dependent parameters influenced by the so-called "flip-flop" phenomena (37) that arise because the absorption kinetics of the sustained release formulations are slower than the corresponding systemic elimina- tion. The absence of suitable i.v. NVP rat PK data precluded comodeling to force the systemic and peripheral values of V and CL and subsequently determine physically meaningful absorption rate constant (K a ) values for both formulations. A modeling approach therefore was adopted that optimized K a , V, and CL to best fit the observed profiles, with respect to the maximum concentration of drug in serum (C max ) and the time to maximum concentration of drug in serum (T max ); therefore, the PK parameters for both formulations shown in Table 2 cannot be compared directly.
While these values may not represent physical reality, they were useful as a framework for human simulation and to establish quantitative estimates for lead prioritization. Overall, a two-compartment model with linear absorption and linear elimination adequately described the study 1 formulation, while a one-compartment model with linear absorption and saturable elimination adequately described the study 2 formulation. Parameter precision and residual error were lower for the study 1 formulation (see Fig. S1 and S2 in the supplemental material), reflecting the better fit of the model to these formulation data. The subcutaneous bioavailability, F, was assumed to be 100% for both formulations based on previous studies in rats (38) . The rate of absorption for study 2 was greater than that for study 1, indicating that the peak levels were achieved quickly for the study 2 formulation. Bearing the above caveats regarding direct comparison of PK parameters across the two formulations in mind, we determined that the in vivo absorption rate constant (K a ) of NVP LA-2 was 8 times that of NVP LA-1; i.e., NVP LA-1 had a larger (slower) release absorption half-life, t 1/2, a ( Table 2) . This difference cannot be explained in terms of the bioavailability, F, as this would shift the concentrations in the vertical direction (Fig. 3) but would not change the shape of the drug time course profile. The absolute NVP level (C max and area under the curve [AUC]) was lower for study 2, however, due to the lower dose, higher volume, and clearance and/or different bioavailability.
Implications for HIV prevention in breastfeeding infants.
The sustained-release NVP formulations described here are intended primarily for HIV-1 prevention of MTCT, not HAART regimens. Prophylactic efficacy in breastfeeding neonates of HIVpositive mothers requires sustained infant NVP blood exposure that significantly exceeds the 90% inhibitory concentration (IC 90 ) value of the drug (39, 40) , although the protective concentration threshold is unknown. The IC 90 for NVP has been reported for different HIV strains: wild-type HXB2, 40 Ϯ 16 ng ml Ϫ1 (150 Ϯ 59 nM); wild-type NL4-3, 32 Ϯ 14 ng ml Ϫ1 (120 Ϯ 52 nM) (41). HIVNET 023 was a phase 1/2 open-label randomized trial designed to determine the safety and minimum dosing schedule of NVP for maintaining a trough plasma drug concentration of Ͼ100 ng ml Ϫ1 among breastfeeding infants for 24 weeks (42). Based on these values and newborn NVP plasma drug data from clinical studies (20, 21, 43) , a conservative lower prophylactic NVP infant plasma drug concentration of 0.2 g ml Ϫ1 (5 times the IC 90 ) is targeted here. Steady-state NVP plasma levels of 3 g ml Ϫ1 are generally considered safe and represent a therapeutic target (44, 45) . Based on this analysis, it is proposed that a long-acting NVP formulation should maintain infant drug plasma levels between 0.2 and 3.0 g ml Ϫ1 . Combining the presystemic absorption rate constants obtained from rats, which provide estimates of the rate-limiting release from the microparticles, with the systemic parameters of NVP following oral administration in infants, the performance of these formulations in pediatric subjects at the proposed dose regimen can be determined via simulation.
Simulations showed that both formulations administered via subcutaneous injection at less than the daily oral adult 200-mg NVP dose would maintain NVP plasma levels in the above target range, or longer, in infants. The NVP LA-1 simulation (Fig. 4A and B) predicts plasma NVP levels dropping to ca. 0.2 g ml Ϫ1 within a few weeks after dosing. When administered as a 60-mg dose, NVP LA-2 is pre- dicted to maintain NVP plasma levels in the target 0.2 to 3.0 g ml Ϫ1 range for 90 days or longer (Fig. 4C and D) .
Based on these encouraging results, we have applied for and received (25 November 2009) orphan drug designation for NVP in the "prevention of HIV infection in pediatric patients under the age of 16 years" (http://www.accessdata.fda.gov/scripts/opdlisting /oopd/OOPD_Results_2.cfm?Index_Numberϭ293409).
In conclusion, long-acting NVP has translational potential as a candidate regimen for HIV prophylaxis in breastfeeding infants in resource-constrained regions. Sustained-release NVP delivery and distribution might improve drug adherence and reduce transmission compared to regimens with daily dosing. This innovative approach is in alignment with World Health Organization guidelines.
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